Krystal Biotech (FRA:4KB) Accounts Payable & Accrued Expense : €69.1 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech Accounts Payable & Accrued Expense?

Krystal Biotech's quarterly accounts payable & accrued expense increased from Sep. 2024 (€77.2 Mil) to Dec. 2024 (€93.9 Mil) but then declined from Dec. 2024 (€93.9 Mil) to Mar. 2025 (€69.1 Mil).

Krystal Biotech's annual accounts payable & accrued expense increased from Dec. 2022 (€25.5 Mil) to Dec. 2023 (€27.0 Mil) and increased from Dec. 2023 (€27.0 Mil) to Dec. 2024 (€93.9 Mil).

Krystal Biotech Accounts Payable & Accrued Expense Historical Data

The historical data trend for Krystal Biotech's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Accounts Payable & Accrued Expense Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.91

21.78

25.51

26.98

93.95

Krystal Biotech Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															40.06	63.16	77.15	93.95	69.13

Krystal Biotech Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Krystal Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

KRYS:USA

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines